134 related articles for article (PubMed ID: 35098372)
1. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
Casas R; Dietrich F; Puente-Marin S; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Acta Diabetol; 2022 May; 59(5):687-696. PubMed ID: 35098372
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
[TBL] [Abstract][Full Text] [Related]
3. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
[TBL] [Abstract][Full Text] [Related]
4. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Front Immunol; 2020; 11():564921. PubMed ID: 33162978
[TBL] [Abstract][Full Text] [Related]
5. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2022 Mar; 38(3):e3500. PubMed ID: 34611978
[TBL] [Abstract][Full Text] [Related]
6. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Chéramy M; Skoglund C; Johansson I; Ludvigsson J; Hampe CS; Casas R
Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
[TBL] [Abstract][Full Text] [Related]
7. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
Tavira B; Cheramy M; Axelsson S; Åkerman L; Ludvigsson J; Casas R
Diabetologia; 2017 Jul; 60(7):1276-1283. PubMed ID: 28357504
[TBL] [Abstract][Full Text] [Related]
8. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
[TBL] [Abstract][Full Text] [Related]
9. Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
Nowak C; Lind M; Sumnik Z; Pelikanova T; Nattero-Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Hanas R; Hernandez C; Clemente-León M; Gómez-Gila A; Ferrer Lozano M; Sas T; Pruhova S; Dietrich F; Puente-Marin S; Hannelius U; Casas R; Ludvigsson J
J Clin Endocrinol Metab; 2022 Aug; 107(9):2644-2651. PubMed ID: 35665810
[TBL] [Abstract][Full Text] [Related]
10. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
[TBL] [Abstract][Full Text] [Related]
11. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
Krause S; Landherr U; Agardh CD; Hausmann S; Link K; Hansen JM; Lynch KF; Powell M; Furmaniak J; Rees-Smith B; Bonifacio E; Ziegler AG; Lernmark A; Achenbach P
Diabetes Care; 2014 Jun; 37(6):1675-80. PubMed ID: 24598244
[TBL] [Abstract][Full Text] [Related]
12. Combined Etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes.
Ludvigsson J; Routray I; Vigård T; Hanås R; Rathsman B; Carlsson A; Särnblad S; Albin AK; Arvidsson CG; Samuelsson U; Casas R
Diabetes Metab Res Rev; 2021 Oct; 37(7):e3440. PubMed ID: 33486892
[TBL] [Abstract][Full Text] [Related]
13. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
Axelsson S; Chéramy M; Akerman L; Pihl M; Ludvigsson J; Casas R
Diabetes Care; 2013 Nov; 36(11):3418-24. PubMed ID: 23863909
[TBL] [Abstract][Full Text] [Related]
14. Latent Autoimmune Diabetes in Adults: Background, Safety and Feasibility of an Ongoing Pilot Study With Intra-Lymphatic Injections of GAD-Alum and Oral Vitamin D.
Björklund A; Hals IK; Grill V; Ludvigsson J
Front Endocrinol (Lausanne); 2022; 13():926021. PubMed ID: 35923626
[TBL] [Abstract][Full Text] [Related]
15. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
Elding Larsson H; Lundgren M; Jonsdottir B; Cuthbertson D; Krischer J;
Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
[TBL] [Abstract][Full Text] [Related]
17. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
[TBL] [Abstract][Full Text] [Related]
18. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Ludvigsson J; Krisky D; Casas R; Battelino T; Castaño L; Greening J; Kordonouri O; Otonkoski T; Pozzilli P; Robert JJ; Veeze HJ; Palmer J; Samuelsson U; Elding Larsson H; Åman J; Kärdell G; Neiderud Helsingborg J; Lundström G; Albinsson E; Carlsson A; Nordvall M; Fors H; Arvidsson CG; Edvardson S; Hanås R; Larsson K; Rathsman B; Forsgren H; Desaix H; Forsander G; Nilsson NÖ; Åkesson CG; Keskinen P; Veijola R; Talvitie T; Raile K; Kapellen T; Burger W; Neu A; Engelsberger I; Heidtmann B; Bechtold S; Leslie D; Chiarelli F; Cicognani A; Chiumello G; Cerutti F; Zuccotti GV; Gomez Gila A; Rica I; Barrio R; Clemente M; López Garcia MJ; Rodriguez M; Gonzalez I; Lopez JP; Oyarzabal M; Reeser HM; Nuboer R; Stouthart P; Bratina N; Bratanic N; de Kerdanet M; Weill J; Ser N; Barat P; Bertrand AM; Carel JC; Reynaud R; Coutant R; Baron S
N Engl J Med; 2012 Feb; 366(5):433-42. PubMed ID: 22296077
[TBL] [Abstract][Full Text] [Related]
19. Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies.
Salami F; Spiliopoulos L; Maziarz M; Lundgren M; Brundin C; Bennet R; Hillman M; Törn C; Elding Larsson H
J Immunol Res; 2022; 2022():3532685. PubMed ID: 35664355
[TBL] [Abstract][Full Text] [Related]
20. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
Skoglund C; Chéramy M; Casas R; Ludvigsson J; Hampe CS
Pediatr Diabetes; 2012 May; 13(3):244-50. PubMed ID: 21848927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
